Libaccord
Supercooled Liquid Nitrogen for Treatment of Arrhythmia
Company Overview
Snapshot
Founded in March 2020 by Gregory Golovchiner and Yakov Nedlin, Libaccord operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing an innovative medical device.
Business overview
Libaccord is a medical technology company specializing in the treatment of ventricular and atrial arrhythmias. The company's core product is an innovative device that utilizes supercooled liquid nitrogen to achieve deep, transmural ablation. This solution employs a novel clinical approach of scar homogenization to reduce procedure time and integrates built-in ablation depth feedback for enhanced performance and safety. Libaccord operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets, serving healthcare providers globally.
Strategic signal
In January 2022, Libaccord's innovative approach to arrhythmia treatment was highlighted in a feature by Haaretz. This coverage underscores the company's progress in developing its supercooled liquid nitrogen technology, signaling potential for disruption in the cardiovascular medical device market and validating its R&D efforts to investors and innovation teams.
Log in to access full profile ›Company Intelligence Q&A
- What is Libaccord's primary focus?
- Libaccord is focused on developing an innovative device for treating ventricular and atrial arrhythmias using supercooled liquid nitrogen.
- When was Libaccord founded?
- Libaccord was founded in March 2020.
- Who are the founders of Libaccord?
- Libaccord was co-founded by Gregory Golovchiner and Yakov Nedlin.
- What is the core technology behind Libaccord's solution?
- Libaccord's core technology utilizes supercooled liquid nitrogen for transmural ablation, incorporating scar homogenization and built-in ablation depth feedback.
- In which sector does Libaccord primarily operate?
- Libaccord operates primarily in the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics.